Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 1.00 |
| ▸ | TOP2B | Q02880 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icrf-193 SCHEMBL14006976 | 1.00 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL27318121 | 1.00 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL729019 | 1.00 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL18618027 | 0.87 | TOP2A (0.76) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL728997 | 0.84 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL13857354 | 0.84 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL19505555 | 0.84 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL727291 | 0.81 | TOP2A (0.67) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL9752440 | 0.81 | TOP2A (0.66) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL14006912 | 0.80 | TOP2A (0.65) | TOP2ATOP2BALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382499-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2024-11-21 | — | — | US | disclosed |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| EP-4277706-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022154664-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-07-21 | — | — | WO | disclosed |
| WO-2021144746-A1 | USE OF ICRF-193 DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF FOR THE PREVENTION OF CHRONIC CUMULATIVE CARDIOTOXICITY CAUSED BY THERAPY WITH ANTHRACYCLINE ANTICANCER DRUGS | UNIVERZITA KARLOVA V PRAZE (CZ) | 2021-07-22 | — | — | WO | disclosed |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10722530-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-10725042-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIV CASE WESTERN RESERVE (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | disclosed |
| EP-0491053-B1 | WATER-SOLUBLE BIS-DIOXOPIPERAZINE DERIVATIVES WITH ANTITUMORAL PROPERTIES | ZENYAKU KOGYO KK (JP) | 1996-02-07 | — | — | EP | disclosed |
| US-5393889-A | Antitumor agents | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1995-02-28 | — | — | US | disclosed |
| EP-0256137-B1 | BIS-DIOXOPIPERAZINE DERIVATIVES | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1992-12-23 | — | — | EP | disclosed |
| EP-0491053-A1 | WATER-SOLUBLE BIS-DIOXOPIPERAZINE DERIVATIVES WITH ANTITUMORAL PROPERTIES | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1992-06-24 | — | — | EP | disclosed |
| EP-0230474-B1 | BIS-DIOXOPIPERAZINE DERIVATIVES AND DRUG COMPOSITION CONTAINING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4877803-A | ANTITUMOR AGENTS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-10-31 | — | — | US | disclosed |
| US-4868303-A | ANTITUMOR | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-09-19 | — | — | US | disclosed |
| EP-0256137-A1 | BIS-DIOXOPIPERAZINE DERIVATIVES | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1988-02-24 | — | — | EP | disclosed |
| EP-0230474-A1 | BIS-DIOXOPIPERAZINE DERIVATIVES AND DRUG COMPOSITION CONTAINING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1987-08-05 | — | — | EP | disclosed |
| US-4275063-A | 1,2-BIS(3,5-DIOXOPIPERAZIN-YL)PROPANE FOR TREATMENT OF CANCER IN HUMANS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722530-B2 | Methods of diagnosing and treating cancer | UNG, TP53, OGG1 | TOP2A 26/4885TOP2B 65/4885ALDH1A1 372/4885 |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, TP53, OGG1 | TOP2A 26/4885TOP2B 65/4885ALDH1A1 372/4885 |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PARP2, PARP1, PPP2CA | TOP2A 29/4885TOP2B 34/4885ALDH1A1 2368/4885 |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | UNG, OGG1, MPG | TOP2A 25/4885TOP2B 36/4885ALDH1A1 747/4885 |
| US-10725042-B2 | Methods of diagnosing and treating cancer | UNG, NTPCR, GUSB | TOP2A 75/4885TOP2B 111/4885ALDH1A1 156/4885 |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | ABCC1, TSG101, BRCA1 | TOP2A 10/4885TOP2B 21/4885ALDH1A1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.